Astellas taps GO’s glycoprotein platform with $783.5m deal
pharmaphorum
JUNE 1, 2022
Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targets. The Japanese drugmaker is paying $20.5
Let's personalize your content